Life sciences innovation

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing RNA interference therapeutics that 'silences' Messenger RNAs implicated in the cause of diseases. Alnylam delivered the world's first approved RNAi therapeutic treatment in 2018 and has developed three other first-in-class RNAi-based medicines.

Omega Therapeutics

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines designed to controllably modulate gene expression to treat or cure diseases.

Fulcrum Therapeutics

Fulcrum Therapeutics specialises in developing treatments for genetic diseases that are largely overlooked by mainstream medicine. By adapting gene expression, disorders can be treated at their root cause.

Medovate

Medovate works collaboratively with clinical innovators and the NHS to develop, manufacture and bring to market new medical devices to improve patient safety and care. 

Kynos Therapeutics

Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. Their medicines block the action of KMO - a key enzyme at the interface of inflammation, immunity and metabolism.

Global Access Dx (GADx)

GADx is a leading developer and manufacturer of advanced lateral flow and rapid diagnostic technologies. Leveraging their core technology platforms, they work with governments and international organisations, reinvesting their profits to deliver high quality and affordable diagnostics.